Mallinckrodt agreed to acquire InfaCare Pharmaceutical, gaining stannsoporfin, a Phase 3 heme oxygenase inhibitor in development for severe neonatal hyperbilirubinemia. Deal structure: $80M upfront plus up to $345M in development, regulatory and sales-based milestones (~$425M aggregate). The deal expanded Mallinckrodt's hospital/specialty franchise. Stannsoporfin later faced an FDA refuse-to-file letter.